By Denny Jacob
Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.
The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research.
Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter.
Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial.
Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer.
Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sciences.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 27, 2025 07:56 ET (11:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。